VivoSeq
Other

Myeloid

4

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Myeloid is an early-stage landscape with 4 programs across 4 companies. The most active players are Sanofi, Akero Therapeutics, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2Novartis logo

Novartis

2 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

9

clinical trials

Completed3 · 33%
Recruiting3 · 33%
Terminated2 · 22%
Withdrawn1 · 11%

Clinical Trials

Trial Activity

9 trials

A Non-Interventional Study on the Tolerability, Safety and Effectiveness of Asciminib in Newly Diagnosed and Pre-treated Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany - the ASC2ADHERE Study
Recruiting·Novartis logoNovartis·N/A·NCT07549516·380 enrolled
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inhibitors
Recruiting·Novartis logoNovartis·Preclinical·NCT04925479·34 enrolled
A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine/Busulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk AML, CML, and MDS
Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT06802315·38 enrolled
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Completed·—·Phase 1·NCT02916979·20 enrolled
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05024994·12 enrolled
A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
Completed·VVersailles Hospital·Preclinical·NCT02428543·49 enrolled
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Terminated·FFox Chase Cancer Center·Phase 2·NCT03302247·3 enrolled
Connect® Myeloid Disease Registry
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT01688011·2,013 enrolled
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Withdrawn·OOncology Institute of Southern Switzerland·N/A·NCT03274778

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)